Ascendis Pharma A/S (ADR)

Factors to consider:

• Total employees count: 55 as of 2014
• Current price 30.3% above estimated high
• Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

• 2024-12-31 to 2025-12-31 estimated range: [68.36$, 160.06$]
• 2025-12-31 to 2026-12-31 estimated range: [51.13$, 123.95$]

Financial Metrics affecting the ASND estimates:

• Negative: with PPE of -19.6 at the end of fiscal year the price was very high
• Negative: negative Operating income
• Negative: Operating cash flow per share per price, % of -4.00 <= 0.33
• Negative: Shareholder equity ratio, % of -8.96 <= 18.93
• Negative: negative Industry operating cash flow (median)
• Negative: negative Net income
• Positive: Investing cash flow per share per price, % of 0.09 > -0.66
• Negative: negative Industry operating income (median)
• Positive: Industry inventory ratio change (median), % of 0 <= 0
• Positive: Interest expense per share per price, % of 0.86 <= 3.41